Vildagliptin NEW
| Price | $50 | $61 | $85 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-07-27 |
Product Details
| Product Name: Vildagliptin | CAS No.: 274901-16-5 |
| Purity: 99.84% | Supply Ability: 10g |
| Release date: 2026/07/27 |
Product Introduction
Bioactivity
| Name | Vildagliptin |
| Description | Vildagliptin (LAF237) is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine. |
| In vitro | In obese male Zucker rats, oral administration of Vildagliptin (10 μmol/kg, p.o.) during a glucose tolerance test increases GLP-1 levels, additionally stimulates insulin secretion, and significantly reduces fluctuations in blood glucose levels. In cynomolgus monkeys treated with Vildagliptin (1 μmol/kg, p.o.), plasma DPP-IV activity is maximally inhibited (95%) approximately 2 hours post-treatment, with inhibition >50% occurring within 30 minutes and lasting over 10 hours. In adult male Sprague-Dawley rats induced with diabetes by Streptozotocin, Vildagliptin treatment of 10 mg/kg for 32 weeks prevents nerve fiber loss. At a dosage of 60 mg/kg, Vildagliptin enhances β-cell replication and decreases apoptosis, leading to an increase in pancreatic β-cell mass, which remains elevated for 12 days post withdrawal of Vildagliptin. |
| In vivo | As the most stable DPP-4 inhibitor, Vildagliptin binds to the DPP-4 S1 and S2 catalytic sites, mimicking the transition state of the P-1 site. |
| Storage | Store at low temperature Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 56 mg/mL (184.57 mM), Sonication is recommended. DMSO : 250 mg/mL (823.99 mM), Sonication is recommended. H2O : 55 mg/mL (181.28 mM), Sonication is recommended. |
| Keywords | Vildagliptin | peptidase | NVP-LAF-237 | NVP-LAF237 | LAF-237 | LAF 237 | Inhibitor | inhibit | Ferroptosis | DPP-IV | DPP-4 | DPP4 | DPP | Dipeptidyl Peptidase | dipeptidyl | cells | Caco-2 | Apoptosis | antihyperglycemic |
| Inhibitors Related | Stavudine | Aceglutamide | Adenosine | Hemin | Urea | Tamoxifen | Metronidazole | Formamide | Dimethyl phthalate | Alginic acid | Dextran sulfate sodium salt (MW 5000) | Sildenafil citrate |
| Related Compound Libraries | Highly Selective Inhibitor Library | Apoptosis Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-08-05 | ||
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-08-05 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-08-05 | ||
|
VIP6Y
|
Sinoway Industrial co., ltd.
|
2026-08-04 | ||
| $34.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2026-07-09 | |
| $5.00 |
Wuhan JiyunZen Tech Co., Ltd.
|
2026-04-10 | ||
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2025-12-24 | ||
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2025-08-21 | |||
|
Hebei Yanxi Chemical Co., Ltd.
|
2025-06-20 | |||
|
PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD
|
2025-05-12 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY